PP2A-Mediated Anticancer Therapy
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
PP2A is a family of mammalian serine/threonine phosphatases that is involved in the control of many cellular functions including protein synthesis, cellular signaling, cell cycle determination, apoptosis, metabolism, and stress responses through the negative regulation of signaling pathways initiated by protein kinases. Rapid progress is being made in the understanding of PP2A complex and its functions. Emerging studies have correlated changes in PP2A with human diseases, especially cancer. PP2A is comprised of 3 subunits: a catalytic subunit, a scaffolding subunit, and a regulatory subunit. The alternations of the subunits have been shown to be in association with many human malignancies. Therapeutic agents targeting PP2A inhibitors or activating PP2A directly have shed light on the therapy of cancers. This review focuses on PP2A structure, cancer-associated mutations, and the targeting of PP2A-related molecules to restore or reactivate PP2A in anticancer therapy, especially in digestive system cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159 · cited 1×
“This review focuses on PP2A structure, cancer-associated mutations, and the targeting of PP2A-related molecules to restore or reactivate PP2A in anticancer therapy, especially in digestive system cancer therapy.”
BackgroundSelf-citationRetractedCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 675429, 10 pages http://dx.doi.org/10.1155/2013/675429”
BackgroundInfluentialCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 1×
“It can directly bind to c-Myc through recognition of the Ser62 site and then prevent PP2Adependent dephosphorylation of c-Myc [31].”
BackgroundCrystal structure of a protein phosphatase 2A heterotrimeric holoenzyme
Cho, U. S., & Xu, W. (2007) · Nature · doi:10.1038/nature05351 · Cited by 459 · cited 1×
“The HEAT repeats of the scaffold A subunit form a horseshoe-shaped fold, holding the catalytic C and regulatory B subunits together on the same side [11].”
BackgroundProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · cited 10×
“STRN3 14q12 PR112, PR102,PR94 nucleus [1, 25, 54]”
InfluentialPP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)
Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390 · cited 1×
“Phosphorylation at Thr304 is regulated by autophosphorylation-activated protein kinase and can inhibit the recruitment of B55 subunits [7, 8].”
BackgroundIdentification of specific PP2A complexes involved in human cell transformation
Chen, W., Possemato, R., Campbell, K. T., Plattner, C. A., Pallas, D. C., & Hahn, W. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00026-1 · Cited by 325 · cited 2×
“The overexpression of PR65γ in human embryonic kidney epithelial cells and human hepatocellular cell lines can revert the cell transformation [18] (Table 1).”
BackgroundSelf-citationCalin, G. A., di Iasio, M. G., Caprini, E., Vorechovsky, I., Natali, P. G., Sozzi, G., Croce, C. M., Barbanti-Brodano, G., Russo, G., & Negrini, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203389 · Cited by 219 · cited 1×
“This review focuses on PP2A structure, cancer-associated mutations, and the targeting of PP2A-related molecules to restore or reactivate PP2A in anticancer therapy, especially in digestive system cancer therapy.”
BackgroundMoreno, C. S., Park, S., Nelson, K., Ashby, D., Hubalek, F., Lane, W. S., & Pallas, D. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5257 · Cited by 194 · cited 1×
“PR93, also termed S/G2 nuclear autoantigen (SG2NA), is mainly distributed in the brain and muscle while PR110, also termed striatin mainly in the postsynaptic densities of neuronal dendrites [22].”
BackgroundTargeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
Switzer, C. H., Cheng, R. Y. S., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P. (2011) · Oncogene · doi:10.1038/onc.2010.622 · Cited by 171
A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation
Ito, A., Kataoka, T. R., Watanabe, M., Nishiyama, K., Mazaki, Y., Sabe, H., Kitamura, Y., & Nojima, H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.562 · Cited by 159 · cited 1×
“This review focuses on PP2A structure, cancer-associated mutations, and the targeting of PP2A-related molecules to restore or reactivate PP2A in anticancer therapy, especially in digestive system cancer therapy.”
BackgroundEffect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A
Bos, C. L., Kodach, L. L., van den Brink, G. R., Diks, S. H., van Santen, M. M., Richel, D. J., Peppelenbosch, M. P., & Hardwick, J. C. H. (2006) · Oncogene · doi:10.1038/sj.onc.1209658 · Cited by 156
Christensen, D. J., Ohkubo, N., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., Colton, C. A., & Vitek, M. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002847 · Cited by 125 · cited 1×
“It is reported to increase PP2A activity by upregulating PP2AC subunits, which results in the repression of Akt activation and the subsequent apoptosis [53].”
BackgroundCIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122 · cited 1×
“CIP2A is reported to be a target of bortezomib in many kinds of malignancies, such as HCC, leukemia, human triple negative breast cancer, and head and neck squamous cell carcinoma [32, 33].”
Background
Cited by
The role of CIP2A in cancer: A review and update
Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72
Zhuang, Q., Zhou, T., He, C., Zhang, S., Qiu, Y., Luo, B., Zhao, R., Liu, H., Lin, Y., & Lin, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0341-z · Cited by 38
“Moreover, other studies have demonstrated that the regulation of regulatory B subunits of PP2A (PP2A-Bs), such as B55β and B56γ, play important roles in cancer development or treatment [27].”
BackgroundConditional knockout in mice reveals the critical roles of Ppp2ca in epidermis development
Fang, C., Li, L., & Li, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050756 · Cited by 15
“As a tumor suppressor gene, Ppp2ca is a hotspot for tumor treatment [16].”
BackgroundTargeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Chen, W., Wang, Z., Jiang, C., & Ding, Y.
- Venue
- Gastroenterology Research and Practice
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-10
- ISSN
- 1687-6121 (ISSN-L)
- 1687-630X
- OpenAlex
- W2168928584
- Cited by
- 57
- References
- 14
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.